While survodutide’s 16.6% overall weight loss was underwhelming, Boehringer Ingelheim and Zealand Pharma’s drug achieved “impressive” fat loss, according to BMO Capital Markets.

Original title: “ADA: Boehringer leans on fat mass benefits as obesity bet delivers ‘less competitive’ weight reduction”

Much work needs to be done for Pfizer to be able to catch up to the weight-loss frontrunners, according to Guggenheim Partners, but new data from Metsera’s lead asset could set the pharma apart from competitors with a monthly injection.

Original title: “ADA: Metsera asset data support Pfizer's ‘entry point’ into obesity market”

Racing the clock: How precision logistics deliver life-saving nuclear medicine.

Original title: “Precision under pressure: Logistic solutions for nuclear medicine scalability”

In biopharma, the next edge may come from the systems that turn discovery into scale.

Original title: “Innovation alone is no longer enough in biopharma”

Eli Lilly sauntered into the American Diabetes Association meeting with a commanding lead in the metabolic space and put down more evidence for its pipeline, including new pill Foundayo and next-gen asset retatrutide, in new indications.

Original title: “ADA: Lilly’s weight loss mastery shows benefits in menopause, sleep apnea, more”

A possible alternative to “anti-CGRP” medications, the drug didn’t meet some analysts’ expectations in mid-stage testing but still convinced Lundbeck to pursue further development.

Original title: “Study data convince Lundbeck to push new migraine drug forward”

The American Diabetes Association's annual congress will feature a superstar lineup, including weight loss giants Eli Lilly and Novo Nordisk. But several scrappy biotechs will also present obesity candidates with the potential to match—if not outperform—their deep-pocketed competitors.

Original title: “Lilly and Novo face off at ADA 2026 as others seek to compete in obesity”

While many drugmakers are focused on lung cancer, evidence shows the liver may be a better bet.

Original title: “Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?”

Massachusetts’ life sciences jobs declined 1% in 2025, according to a new MassBioEd report. However, the report is projecting industry employment will increase 9.7% by 2030. It also noted reskilling needs for some roles, including scientists.

Original title: “Massachusetts’ life sciences employment dipped last year following 14 years of growth: report”

The RNA-focused drugmaker says Inceptive's tools will help prioritize the best development options as well as speed up the research process.

Original title: “Alnylam, Inceptive ink AI deal potentially worth $2B”

With Germany moving to curb healthcare spending, Eli Lilly and Boehringer Ingelheim have rethought plans to invest in facilities, including a manufacturing plant for GLP-1 drugs.

Original title: “Lilly and Boehringer roll back billions in German investments over health budget cuts”

Voyxact helped preserve kidney function, but left an opening for competing IgAN drugs from Vera and Vertex. Elsewhere, Takeda’s alliance with Innovent paid early dividends and Axsome warded off generic competitors.

Original title: “Otsuka showcases kidney drug data; Pfizer cuts an AI deal”